Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.

Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N, American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association
CA Cancer J Clin. 2010 60 (3): 194-201

PMID: 20124400 · PMCID: PMC3049943 · DOI:10.3322/caac.20061

MeSH Terms (10)

Androgen Antagonists Antineoplastic Agents Cardiovascular Diseases Humans Male Morbidity Prostatic Neoplasms Risk Assessment Risk Factors United States

Connections (1)

This publication is referenced by other Labnodes entities: